UNSPSC 51273947: Menthol/pramoxine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.

UNSPSC 51273947 Menthol/pramoxine is a Commodity code that reflects state and local procurement of pharmaceutical products and over-the-counter remedies, though recent opportunities tagged under this code diverge significantly from the abstract category name. Recent solicitations show state and local governments purchasing naloxone and drug deactivation systems, generic pharmaceuticals through cooperative agreements, and conducting market research on direct-to-manufacturer prescription programs. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Department of Administration's MMCAP). The mix reflects both standalone county acquisitions and statewide cooperative purchasing vehicles that serve multiple state and local participants across jurisdictions.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program, functioning as exploratory procurement ahead of a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) on January 20, 2026, with a March 26, 2026 response deadline, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon. Vendors on MMCAP contracts must supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements, with awards effective July 1, 2026.